PBMs On Capitol Hill: Why Pharma Will Miss Them When They Are Gone

Drug pricing “middlemen” had their day in the hot seat during a Senate Finance Committee hearing on drug pricing. But even amid the finger-pointing between industry and PBMs over the high cost of drugs, the PBM execs offered some strong reminders of their real value to industry in fending off more overt price interventions by government.  

Ocean Sunset
This might look pretty, but the sunset of the PBM era might be followed by price-control nightmares for the pharma industry.

More from Pricing Debate

More from Market Access